O	0	7	Effects	Effect	NNS	B-NP
O	8	10	of	of	IN	B-PP
O	11	12	3	3	CD	B-NP
O	12	13	-	-	HYPH	I-NP
O	13	37	chloromethylthiochromone	chloromethylthiochromone	NN	I-NP
O	37	38	-	-	HYPH	I-NP
O	38	39	1	1	CD	I-NP
O	39	40	,	,	,	I-NP
O	40	41	1	1	CD	I-NP
O	41	42	-	-	HYPH	I-NP
O	42	49	dioxide	dioxide	NN	I-NP
O	50	52	on	on	IN	B-PP
O	53	60	nucleic	nucleic	JJ	B-NP
O	61	65	acid	acid	NN	I-NP
O	65	66	,	,	,	O
O	67	74	protein	protein	NN	B-NP
O	74	75	,	,	,	O
O	76	79	and	and	CC	O
O	80	87	aerobic	aerobic	JJ	B-NP
O	88	91	and	and	CC	I-NP
O	92	101	anaerobic	anaerobic	JJ	I-NP
O	102	112	metabolism	metabolism	NN	I-NP
O	113	115	of	of	IN	B-PP
B-Cell	116	123	Ehrlich	Ehrlich	NNP	B-NP
I-Cell	124	131	ascites	ascite	VBZ	B-VP
I-Cell	132	137	tumor	tumor	NN	B-NP
I-Cell	138	143	cells	cell	NNS	I-NP
O	143	144	.	.	.	O

O	146	147	3	3	CD	B-NP
O	147	148	-	-	HYPH	I-NP
O	148	172	Chloromethylthiochromone	Chloromethylthiochromone	NN	I-NP
O	172	173	-	-	HYPH	I-NP
O	173	174	1	1	CD	I-NP
O	174	175	,	,	,	I-NP
O	175	176	1	1	CD	I-NP
O	176	177	-	-	HYPH	I-NP
O	177	184	dioxide	dioxide	NN	I-NP
O	185	188	was	be	VBD	B-VP
O	189	197	observed	observe	VBN	I-VP
O	198	200	to	to	TO	I-VP
O	201	203	be	be	VB	I-VP
O	204	205	a	a	DT	B-NP
O	206	212	potent	potent	JJ	I-NP
O	213	222	inhibitor	inhibitor	NN	I-NP
O	223	225	of	of	IN	B-PP
B-Cancer	226	233	Ehrlich	Ehrlich	NNP	B-NP
I-Cancer	234	241	ascites	ascite	NNS	I-NP
I-Cancer	242	251	carcinoma	carcinoma	NN	I-NP
O	252	258	growth	growth	NN	I-NP
O	259	262	and	and	CC	O
O	263	264	a	a	DT	B-NP
O	265	273	moderate	moderate	JJ	I-NP
O	274	283	inhibitor	inhibitor	NN	I-NP
O	284	286	of	of	IN	B-PP
B-Cancer	287	288	P	P	NN	B-NP
I-Cancer	288	289	-	-	HYPH	B-NP
I-Cancer	289	292	388	388	CD	I-NP
I-Cancer	293	304	lymphocytic	lymphocytic	JJ	I-NP
I-Cancer	305	313	leukemia	leukemia	NN	I-NP
O	314	320	growth	growth	NN	I-NP
O	321	323	at	at	IN	B-PP
O	324	326	10	10	CD	B-NP
O	327	329	mg	mg	NN	I-NP
O	329	330	/	/	SYM	B-NP
O	330	332	kg	kg	NN	I-NP
O	332	333	/	/	SYM	B-NP
O	333	336	day	day	NN	I-NP
O	336	337	.	.	.	O

O	338	349	Preliminary	Preliminary	JJ	B-NP
O	350	352	in	in	FW	I-NP
O	353	358	vitro	vitro	FW	I-NP
O	359	366	studies	study	NNS	I-NP
O	367	373	showed	show	VBD	B-VP
O	374	378	that	that	IN	B-SBAR
O	379	382	the	the	DT	B-NP
O	383	389	agents	agent	NNS	I-NP
O	390	403	significantly	significantly	RB	B-VP
O	404	413	inhibited	inhibit	VBD	I-VP
O	414	417	RNA	RNA	NN	B-NP
O	418	421	and	and	CC	I-NP
O	422	425	DNA	DNA	NN	I-NP
O	426	435	synthesis	synthesis	NN	I-NP
O	436	438	in	in	IN	B-PP
B-Cell	439	446	Ehrlich	Ehrlich	NNP	B-NP
I-Cell	447	454	ascites	ascite	NNS	I-NP
I-Cell	455	460	cells	cell	NNS	I-NP
O	460	461	.	.	.	O

O	462	464	In	In	FW	B-NP
O	465	469	vivo	vivo	FW	I-NP
O	470	477	studies	study	NNS	I-NP
O	478	483	after	after	IN	B-PP
O	484	490	dosing	dosing	NN	B-NP
O	491	493	on	on	IN	B-PP
O	494	498	Days	Day	NNS	B-NP
O	499	500	6	6	CD	I-NP
O	500	501	,	,	,	I-NP
O	502	503	7	7	CD	I-NP
O	503	504	,	,	,	O
O	505	508	and	and	CC	O
O	509	510	8	8	CD	B-NP
O	511	523	demonstrated	demonstrate	VBD	B-VP
O	524	527	the	the	DT	B-NP
O	528	532	same	same	JJ	I-NP
O	533	543	reductions	reduction	NNS	I-NP
O	544	546	in	in	IN	B-PP
O	547	554	nucleic	nucleic	JJ	B-NP
O	555	559	acid	acid	NN	I-NP
O	560	569	synthesis	synthesis	NN	I-NP
O	570	573	and	and	CC	O
O	574	575	a	a	DT	B-NP
O	576	584	moderate	moderate	JJ	I-NP
O	585	594	reduction	reduction	NN	I-NP
O	595	597	in	in	IN	B-PP
O	598	605	protein	protein	NN	B-NP
O	606	615	synthesis	synthesis	NN	I-NP
O	615	616	.	.	.	O

O	617	620	The	The	DT	B-NP
O	621	628	primary	primary	JJ	I-NP
O	629	633	site	site	NN	I-NP
O	634	636	of	of	IN	B-PP
O	637	644	nucleic	nucleic	JJ	B-NP
O	645	649	acid	acid	NN	I-NP
O	650	659	synthesis	synthesis	NN	I-NP
O	659	660	,	,	,	O
O	661	666	which	which	WDT	B-NP
O	667	670	was	be	VBD	B-VP
O	671	678	blocked	block	VBN	I-VP
O	679	681	by	by	IN	B-PP
O	682	683	3	3	CD	B-NP
O	683	684	-	-	HYPH	I-NP
O	684	708	chloromethylthiochromone	chloromethylthiochromone	NN	I-NP
O	708	709	,	,	,	O
O	710	713	was	be	VBD	B-VP
O	714	716	at	at	IN	B-PP
O	717	726	orotidine	orotidine	NN	B-NP
O	727	740	monophosphate	monophosphate	NN	I-NP
O	741	754	decarboxylase	decarboxylase	NN	I-NP
O	755	757	in	in	IN	B-PP
O	758	761	the	the	DT	B-NP
O	762	771	primidine	primidine	NN	I-NP
O	772	779	pathway	pathway	NN	I-NP
O	779	780	.	.	.	O

O	781	786	Other	Other	JJ	B-NP
O	787	794	enzymes	enzyme	NNS	I-NP
O	794	795	,	,	,	O
O	796	798	in	in	IN	B-PP
O	799	808	anaerobic	anaerobic	JJ	B-NP
O	809	812	and	and	CC	I-NP
O	813	820	aerobic	aerobic	JJ	I-NP
O	821	831	glycolysis	glycolysis	NN	I-NP
O	831	832	,	,	,	O
O	833	838	which	which	WDT	B-NP
O	839	843	were	be	VBD	B-VP
O	844	851	blocked	block	VBN	I-VP
O	852	859	include	include	VBP	B-VP
O	860	870	hexokinase	hexokinase	NN	B-NP
O	870	871	,	,	,	O
O	872	891	phosphofructokinase	phosphofructokinase	NN	B-NP
O	891	892	,	,	,	O
O	893	901	succinic	succinic	JJ	B-ADJP
O	902	905	and	and	CC	O
O	906	911	alpha	alpha	SYM	B-NP
O	911	912	-	-	HYPH	O
O	912	925	ketoglutarate	ketoglutarate	JJ	B-NP
O	926	940	dehydrogenases	dehydrogenas	NNS	I-NP
O	940	941	,	,	,	O
O	942	944	as	as	RB	B-CONJP
O	945	949	well	well	RB	I-CONJP
O	950	952	as	as	IN	I-CONJP
O	953	959	States	State	NNS	B-NP
O	960	961	3	3	CD	B-NP
O	962	965	and	and	CC	I-NP
O	966	967	4	4	CD	I-NP
O	968	970	of	of	IN	B-PP
O	971	980	oxidative	oxidative	JJ	B-NP
O	981	996	phosphorylation	phosphorylation	NN	I-NP
O	996	997	.	.	.	O

